N-(β-Piperidinoethyl)-N-methyl-ethanolamin | 56242-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-(β-Piperidinoethyl)-N-methyl-ethanolamin
• 英文别名: 2-[methyl-(2-piperidin-1-yl-ethyl)-amino]-ethanol；2-[Methyl(2-piperidin-1-ylethyl)amino]ethanol
• CAS: 56242-30-9
• 化学式: C₁₀H₂₂N₂O
• 分子量: 186.297
• InChiKey: JYDUXVBLNWTJKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] BIARYLTRIAZOLE INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR<br/>[FR] INHIBITEURS DE TRIAZOLE BIARYLE DU FACTEUR INHIBITEUR DE LA MIGRATION DES MACROPHAGES
  申请人：UNIV YALE

  公开号：WO2016130968A1

  公开（公告）日：2016-08-18

  The present disclosure describes biaryl triazole compounds, as well as their compositions and methods of use. The compounds inhibit the activity of macrophage migration inhibitory factor and are useful for the treatment of diseases, e.g., inflammatory diseases and cancer.

  本公开描述了联苯三唑化合物，以及它们的组合物和使用方法。这些化合物抑制巨噬细胞迁移抑制因子的活性，并且对于治疗疾病，例如炎症性疾病和癌症，具有用处。
• Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Oka Takahiro

  公开号：US20070049593A1

  公开（公告）日：2007-03-01

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其化学式为[I]，其中每个符号的定义如规范中所述，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物表现出基于HCV聚合酶抑制活性的抗HCV活性，因此可用作预防或治疗丙型肝炎的药物。
• TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
  申请人：Oka Takahiro

  公开号：US20120070409A1

  公开（公告）日：2012-03-22

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其表示为以下公式[I]，其中每个符号如规范中所定义，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物基于HCV聚合酶抑制活性显示出抗HCV活性，可用作预防或治疗丙型肝炎的药物。
• US7977331B1
  申请人：——

  公开号：US7977331B1

  公开（公告）日：2011-07-12